Results grounded in experimental dataβnot abstracts.
Press Enter β΅ to solve
Fuel Your Discoveries
"The beauty of a living thing is not the atoms that go into it, but the way those atoms are put together."
- Carl Sagan
Long Response
Copied
Neuroblastoma risk stratification tables
Epistemic note: You asked for INSS, INPC, and COG risk stratification markers. Your provided research excerpts contain detailed descriptions of some clinical/biologic predictors used in historical/current COG-style risk frameworks, but do not include a complete, canonical, cell-by-cell mapping of every INSS stage and every INPC histology criterion. Therefore, the tables below include only markers/variables that are explicitly supported by the provided sources, and I mark gaps as βNot provided in sourcesβ.
Markers associated with better induction response (COG high-risk pooled data)
End-induction response (PR/CR vs not) was analyzed in a pooled set of COG high-risk trials; the excerpt provides PR-rate differences by baseline variables (e.g., LOH, MKI, age).
Sources:
Table A. INSS staging (clinical staging variables/inputs explicitly supported by sources)
What the provided sources support: the excerpts explicitly mention that INSS staging is part of earlier (historic) clinical classifiers and later harmonization efforts, but the excerpt text you provided does not list every INSS stage definition detail (e.g., exact anatomic criteria for stage 2A vs 2B vs 3). Therefore, this table focuses on markers/inputs that are explicitly described.
INSS-related element
Role in risk classification (from provided excerpts)
Concrete marker/variable described
Source evidence
INSS stage (Evans/INSS stage)
Used in historic criteria summarized as part of CCG/COG-like approaches
Stage category (named in excerpt; precise stage sub-definitions not provided)
Age at diagnosis
Major independent prognostic factor; also used in risk-group classifiers that incorporate clinical stage
Age thresholding (e.g., includes <1 year better prognosis; and example PR rates by <18 months vs β₯18 months)
Primary site / tumor burden proxies
Contributes to prognosis in registry work; not a pure INSS-only marker but used as a clinical variable in older prognostic models
Primary site category; tumor volume (estimated)
Stage 4S special case
Distinct prognosis pattern in registry data
Stage 4S category (favorable prognosis in infants in the registry)
INSS stage definitions (exact criteria)
Not provided in the research excerpts you supplied
Not provided in sources
Gap due to missing criteria text in your supplied excerpts.
Table B. INPC (Shimada) histology: what is explicitly supported and how it functions as a risk input
The provided excerpts confirm that INPC/Shimada histologic classification includes four morphologic categories and is used as a prognostic input, but the excerpt text you provided does not enumerate each categoryβs defining microscopic criteria.
INPC/Shimada element
Marker / variable
Risk-relevant role described
Source evidence
INPC system (Shimada)
Four morphologic histologic categories; favorable vs unfavorable histology
Used in classification frameworks as a clinicopathologic prognostic input
Histology used in current pretreatment frameworks (INRG context)
Histologic category and grade of differentiation (as risk criteria inputs)
Explicitly included as risk classifier components in the INRG pretreatment framework
Table C. COG risk stratification βmarkersβ (variables explicitly supported by provided sources)
Because you requested COG risk stratification markers, this table aggregates risk classifier variables that your excerpts explicitly list as inputs (e.g., age, INSS/INRGSS stage, MYCN, ploidy, 11q status, SCAs, MKI) and also includes induction-response-associated variables where numeric effects were provided.
COG-associated marker/variable
Type (clinical vs biologic)
How it is used (as stated in excerpts)
Evidence from provided research
Whatβs missing / uncertainty
Age
Clinical
Prognostic variable; used in historical and current risk classifiers
Exact COG cutoffs/rules are not fully enumerated in the provided excerpts.
INSS stage / Evans- or INSS stage
Clinical
Used in historic intergroup criteria summarized in review
No detailed INSS-stage criteria text in the supplied excerpt.
INRGSS stage (pretreatment framework)
Clinical
Part of INRG pretreatment risk classifier; used to harmonize classification across groups
COG-to-INRG mapping rules are discussed at a high level but not fully enumerated here.
MYCN status (amplification)
Biologic
Central prognostic classifier variable in multiple frameworks
Assay definitions (FISH thresholding, sequencing thresholds) are not provided in the excerpt.
Tumor cell ploidy
Biologic
Listed as a component of INRG pretreatment risk classifier
Exact ploidy category boundaries (e.g., near-triploid vs near-diploid cutoffs) are not provided in your excerpts.
11q status / 11q LOH
Biologic
Included in INRG pretreatment framework; associated with induction-response differences in high-risk pooled analysis
Your excerpt notes >50% missingness for some biomarker variables, limiting certainty in multivariable interpretations.
1p LOH
Biologic
Reported as a baseline predictor of response in COG pooled analysis
The excerpt provides PR-rate association; it does not provide full COG decision-rule logic for final risk group assignment.
MKI (mitosis-karyorrhexis index)
Biologic (tumor morphology metric)
Explicitly referenced as part of proposed/next-version marker sets and as associated with response-rate differences in pooled analysis
Because your excerpt provides response-rate examples, not full COG risk-group thresholds, the exact mapping to risk group bins is not provided here.
SCAs / copy-number alterations (as general category)
Biologic
Discussed as candidate/important genomic markers for future integration
Specific SCAs used in a precise COG marker checklist are not enumerated in the supplied excerpt.
Critical gaps & limitations (based only on supplied excerpts)
Stage/histology definitions: exact INSS and INPC criterion text is not present in your provided excerpt(s), so I cannot safely reconstruct full official definitions without additional source material.
Biomarker missingness: the COG pooled induction analysis notes substantial missingness for key biomarker variables (e.g., 11q status >50% missing), which can bias multivariable interpretation when feature availability differs by cohort.
Outcome vs response endpoints: the provided numeric examples are primarily about induction response predictors, not a fully enumerated COG risk-group assignment rule set. Response enrichment does not automatically equal long-term risk assignment.
Historical-to-current harmonization: the review excerpt emphasizes that harmonization across regions/eras has been challenging and that integrating new genomic biomarkers is an ongoing effort.
Extract marker names (age, stage, MYCN, ploidy, 11q, 1p, MKI) from cited excerpts, then render them into three normalized tables and a PR-rate bar chart from reported summary percentages.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Science Art
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Long Response
Top Data Sources
ExportMCP
Keep Exploring
Analysis Wizard
Discussion
Fuel Your Discoveries
Ask a Follow-Up
Science Movie